FTC rules Impax received illegal payments to block pain reliever generic
FTC approves Amneal’s $1.45bn acquisition of Impax
Amneal and Impax merge to become ‘fifth largest’ generics company
designer491 / iStockphoto.com
The Federal Trade Commission (FTC) is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at email@example.com.
If you have any technical issues please email tech support.
FTC, Federal Trade Commission, generics, Amneal Pharmaceuticals, Impax Laboratories, mergers and acquisitions, M&S, anticompetitive